EUVIMEDEUVIMED entdecken
Open Access

Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA

Leire Arrizabalaga, Claudia Augusta Di Trani, Celia Gomar, Daniel Moreno-Luqui, Nuria Ardaiz, Virginia Belsue, José González-Gomariz, David Ruiz-Guillamon, Aline Risson, Yufei Zheng, Eduardo Huarte, Ignacio Matos und 3 weitere

Theranostics · 2026

DOI: 10.7150/thno.122132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2026. Verfasst von Leire Arrizabalaga und 14 weiteren Autor:innen. Beteiligte Einrichtung: Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain. Hauptthemen laut MEDLINE: Interleukin-33, Immunotherapy, Adoptive, RNA, Messenger, T-Lymphocytes. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Peritoneal carcinomatosis (PC) remains a major clinical challenge with limited therapeutic options across tumor types. Adoptive cell therapy (ACT) with tumor-specific T cells offers promise, but its efficacy is often impaired by the immunosuppressive tumor microenvironment (TME). Intraperitoneal ACT is under investigation to improve its effectiveness against metastases within the peritoneal cavity. IL-33, a cytokine of the IL-1 family, plays dual roles in immunity and inflammation and may enhance antitumor responses. We evaluated whether IL-33 mRNA-engineered T cells improve ACT efficacy in murine PC models and assessed potential synergy with IL-12 mRNA.

Methods

OT.I, PMEL-1, and CEA-specific CAR T cells were electroporated with mRNA encoding IL-33, IL-12, or an IL-33 mutein. In vitro assays measured cytokine production and cytotoxicity. RNA-seq was performed to analyze transcriptomic changes following IL-33 mRNA electroporation. ST2-/- T cells were used to evaluate the role of IL-33 receptor expression on transferred T cells versus host cells. In vivo studies in murine PC models assessed survival and immune responses using ELISA, ELISpot, and flow cytometry.

Results

IL-33 mRNA-electroporated OT.I T cells exhibited enhanced IFN-γ expression in a ST2-dependent, T cell-intrinsic manner. In vivo, IL-33-engineered T cells significantly improved survival in PC models. IL-33 reshaped the TME by increasing infiltration of innate lymphoid cells and eosinophils while reducing neutrophils. Engineering T cells with a stabilized IL-33 mutein further enhanced antitumor activity. Co-electroporation of IL-33 mutein and IL-12 mRNA in PMEL-1 T cells led to synergistic increases in IFN-γ production, cytotoxicity, and long-term memory, resulting in superior tumor control and protection upon rechallenge. These findings were confirmed using IL-33 mutein/IL-12 mRNA-electroporated CEA CAR T cells in peritoneal tumor models.

Conclusions

IL-33 enhances ACT efficacy by promoting IFN-γ expression via autocrine ST2 signaling and by modulating the TME. The IL-33 mutein improves cytokine stability and antitumor activity, while combination with IL-12 yields synergistic effects. This strategy holds promise for enhancing ACT in peritoneal carcinomatosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-33Immunotherapy, AdoptiveRNA, MessengerT-LymphocytesInterleukin-12Peritoneal NeoplasmsAnimalsMiceInterferon-gammaTumor MicroenvironmentElectroporationInterleukin-1 Receptor-Like 1 ProteinMice, Inbred C57BLElectroporation TherapiesFemaleCell Line, Tumor

Stichwörter der Autor:innen

RNA electroporationT cell therapycytokine engineeringimmune modulationsolid tumor immunotherapytumor microenvironment

Substanzen

Interleukin-33RNA, MessengerInterleukin-12Il33 protein, mouseInterferon-gammaInterleukin-1 Receptor-Like 1 ProteinIl1rl1 protein, mouse

Autor:innen und Institutionen

  • Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.
  • Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
  • Departments of Immunology and Oncology (CCUN), Clínica Universidad de Navarra, Pamplona, Spain.
  • Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Zitieren

APA

Arrizabalaga, L., Di Trani, C. A., Gomar, C., Moreno-Luqui, D., Ardaiz, N., Belsue, V., González-Gomariz, J., Ruiz-Guillamon, D., Risson, A., Zheng, Y., Huarte, E., Matos, I., Melero, I., Berraondo, P., & Aranda, F. (2026). Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA. Theranostics. https://doi.org/10.7150/thno.122132

Vancouver

Arrizabalaga L, Di Trani CA, Gomar C, Moreno-Luqui D, Ardaiz N, Belsue V, et al. Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA. Theranostics. 2026. doi:10.7150/thno.122132

BibTeX
@article{Arrizabalaga2026,
  author = {Arrizabalaga, Leire and Di Trani, Claudia Augusta and Gomar, Celia and Moreno-Luqui, Daniel and Ardaiz, Nuria and Belsue, Virginia and González-Gomariz, José and Ruiz-Guillamon, David and Risson, Aline and Zheng, Yufei and Huarte, Eduardo and Matos, Ignacio and Melero, Ignacio and Berraondo, Pedro and Aranda, Fernando},
  title = {Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA},
  journal = {Theranostics},
  year = {2026},
  doi = {10.7150/thno.122132}
}
Kostenlos starten →